Barely Significant
← all phrases

“nearly significant”

3,288 sentences · 3,288 papers · 3,853 search hits before verification · confirmed specimen

Sighted at

p=0.0579p=0.06

Listed by Hankins, posted since · Hankins (2013) · Otte et al. (2022)

In the literature

In addition, if, for the relative rate test, they had compared the chaetognath to a group of species after removing the very fastly evolving platyhelminth, it is likely that the P-value would have been much smaller than 0.087 (which is nevertheless nearly significant) as I show below.
Among the correlations of gene expression levels with APOBEC-like motif counts and measures of kataegis, significant or nearly significant correlations were observed for UNG expression with kataegis measures ( ρ between − 0.81 and − 0.80, 0.039 ≤ p adj ≤ 0.063, n = 17, N tests = 475) of the T(C>D)D motif in melanoma, and for APOBEC3A expression with motif counts and kataegis measures in renal cell carcinoma ( ρ between 0.93 and 0.98, 0.008 ≤ p adj ≤ 0.087 with n = 8 and N tests = 510 for the T(C>D)R and T(C>D)D motifs; data not shown).
Although ECMO support after HTx is relatively high in our service, it could be explained by the following reasons: a significant increase in the age of the recipients and the percentage of recipients aged more than 60 years; the higher number of patients bridged with VADs, which in our experience more often require postoperative ECMO; despite the nonsignificant increase in the median age of the donors, the percentage of donors aged more than 60 years increased significantly; a nearly significant increase in the ischemic time; and finally an improvement in the global management of ECMO, resulting in a more liberal use of this technique.
Although confirmation in larger series is warranted, our results also showed a parallel, nearly significant correlation between in vitro ADCC efficiency and p65 nuclear translocation, thus suggesting that the improvement in systemic NK cell activation may favor NK cell-dependent mechanisms, particularly trastuzumab-mediated ADCC in the HER2 + subset ( 22 ).